← Leaderboards
Sathyamangla V Prasad
Cleveland Clinic Lerner Com-Cwru
$12,649,847
Attributed
$16,428,074
Total exposure
9
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2008–25$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,428,074 · 9
By mechanism
R01$14,840,743 · 7
R61$1,118,301 · 1
S10$469,030 · 1
Top collaborators
- Serpil C. Erzurum5 shared
- Wai Hong Wilson Tang5 shared
- Mitchell Alan Olman4 shared
- Vara Prasad Vn Josyula2 shared
Most similar at Cleveland Clinic Lerner Com-Cwru
Same institution · by research overlap
- Serpil C. Erzurum$45,061,611
- Wai Hong Wilson Tang$15,125,003
- Kewal Asosingh$2,975,100
- Vara Prasad Vn Josyula$559,151
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingCardiacIn VivoPhosphotransferasesPhosphorylationRegulationDesensitizationPathway InteractionsHeart FailurePhosphatidylinositolsAgonistProtein PhosphataseSignal TransductionProtein DephosphorylationCyclic AmpIn VitroReceptor FunctionDown-RegulationReceptorBeta-Adrenergic ReceptorLeadCellsRecyclingFunctional Disorder
Grant awards (34)
Mitochondria in cardiomyocyte-fibroblast transcellular cross-talk$639,621
R01 · FY2025 · HL · contact PI
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinase$637,731
R01 · FY2025 · HL · contact PI
Small Molecule Therapeutic for Heart Failure$554,801
R61 · FY2025 · HL · contact PI
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinase$624,975
R01 · FY2024 · HL · contact PI
Small Molecule Therapeutic for Heart Failure$563,500
R61 · FY2024 · HL · contact PI
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinase$637,731
R01 · FY2023 · HL · contact PI
TRPV4-PI3K Axis Mediates Pulmonary and Cardiac Fibrosis$563,500
R01 · FY2020 · HL
TRPV4-PI3K Axis Mediates Pulmonary and Cardiac Fibrosis$560,000
R01 · FY2019 · HL
Non-canonical regulation of GRK2 by TNFalpha impairs BetaAR function$396,250
R01 · FY2019 · HL · contact PI
Beta adrenergic receptor resensitization in asthma$396,250
R01 · FY2019 · HL · contact PI
TRPV4-PI3K Axis Mediates Pulmonary and Cardiac Fibrosis$560,000
R01 · FY2018 · HL
Non-canonical regulation of GRK2 by TNFalpha impairs BetaAR function$396,250
R01 · FY2018 · HL · contact PI
Beta adrenergic receptor resensitization in asthma$396,250
R01 · FY2018 · HL · contact PI
TRPV4-PI3K Axis Mediates Pulmonary and Cardiac Fibrosis$560,000
R01 · FY2017 · HL
VEVO 2100 for a Core Facility$469,030
S10 · FY2017 · OD · contact PI
Beta adrenergic receptor resensitization in asthma$396,250
R01 · FY2017 · HL · contact PI
Novel Regulation of Beta Andregenic Receptor Function$396,250
R01 · FY2017 · HL · contact PI
Non-canonical regulation of GRK2 by TNFalpha impairs BetaAR function$396,250
R01 · FY2017 · HL · contact PI
Pulmonary Vascular-Right Ventricular Axis Research Program$616,195
R01 · FY2016 · HL
Non-canonical regulation of GRK2 by TNFalpha impairs BetaAR function$396,250
R01 · FY2016 · HL · contact PI
Beta adrenergic receptor resensitization in asthma$396,250
R01 · FY2016 · HL · contact PI
Novel Regulation of Beta Andregenic Receptor Function$396,250
R01 · FY2016 · HL · contact PI
Pulmonary Vascular-Right Ventricular Axis Research Program$598,377
R01 · FY2015 · HL
Novel Regulation of Beta Andregenic Receptor Function$390,306
R01 · FY2015 · HL · contact PI
Pulmonary Vascular-Right Ventricular Axis Research Program$630,295
R01 · FY2014 · HL
Novel Regulation of Beta Andregenic Receptor Function$396,250
R01 · FY2014 · HL · contact PI
Pulmonary Vascular-Right Ventricular Axis Research Program$627,903
R01 · FY2013 · HL
Pulmonary Vascular-Right Ventricular Axis Research Program$673,220
R01 · FY2012 · HL
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinas$382,388
R01 · FY2012 · HL · contact PI
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinas$386,250
R01 · FY2011 · HL · contact PI
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinas$386,250
R01 · FY2010 · HL · contact PI
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinas$386,250
R01 · FY2009 · HL · contact PI
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinas$234,751
R01 · FY2009 · HL · contact PI
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinas$386,250
R01 · FY2008 · HL · contact PI